Moderna fell in trading on Thursday after its vaccine revenues missed analysts’ expectations and the company made a small increase in product sales projections for the year.
While Moderna recorded its first profitable quarter, revenues of $1.94bn came in below Wall Street expectations. The 4.3% increase in projected annual product sales to $19.2bn pales in comparison to the $26bn that rival Pfizer now expects from Covid vaccine sales this year.
The final count depends on the mix of primary two-dose vaccine and booster shots that use less vaccine material.
لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر: